Positive Phase III result for opioid alternative cebranopadol

24 January 2025

New Jerseyan biopharmaceutical company Tris Pharma has announced encouraging top-line data from its Phase III ALLEVIATE-1 trial testing cebranopadol as an option for acute pain.

Data show the first-in-class dual-receptor agonist could be an effective treatment for moderate-to-severe pain, and a valuable alternative to opioid analgesics.

The trial demonstrated that cebranopadol significantly reduced pain intensity over 48 hours compared to placebo, with a favorable safety profile. Patients receiving the drug reported no serious side effects, and the most common adverse event was nausea.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical